H.C. Wainwright analyst Andrew Fein reiterated a Neutral rating on Terns Pharmaceuticals (NASDAQ: TERN).The analyst commented: "Terns reported relatively lackluster ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE